Background {#Sec1}
==========

Tonsillar disease is one of the most common disorders in the field of otorhinolaryngology. Different types of tonsillar disease include recurrent tonsillitis and tonsillar hypertrophy, with both leading to symptoms of mouth breathing, snoring, dyspnea, apnea or dysphagia. Treatment is usually antibiotics or tonsillectomy.

Tonsils are secondary lymphoid organs, which are centrally located at the beginning of the respiratory and gastrointestinal tracts where the immune system first comes into contact with infections agents and allergens \[[@CR1]\]. Surgically removed palatine tonsils provide a conventional accessible source to study the interplay between foreign pathogens, allergens and the host immune system. Our previous studies demonstrated that tonsils are organs where immune regulation takes place in which allergen-specific regulatory T cells can be generated by mechanisms depending on plasmacytoid dendritic cells \[[@CR2], [@CR3]\]. The expression of T cell- and interferon specific genes in tonsils has been shown to be closely related to existing viral infections, age, and allergic illnesses \[[@CR4], [@CR5]\]. However, data are scarce on the differences in tonsillar virus infections and immune responses between patients with tonsillar hypertrophy or recurrent tonsillitis \[[@CR6]--[@CR8]\].

Tonsils appear to provide a good in vivo model for investigating the mechanisms of inflammatory processes and infections in lymphoid organs \[[@CR2]--[@CR5]\]. Therefore, we studied whether virus detection and T cell and interferon gene expressions differed between the two main indications of surgery, tonsillar hypertrophy or recurrent tonsillitis.

Methods {#Sec2}
=======

Patients {#Sec3}
--------

Human tonsil samples used in this study were acquired from 200 consecutive tonsillectomy patients who underwent tonsillectomy in Satakunta Central Hospital, Pori, Finland between April 2008 and March 2009. The inclusion criteria were elective tonsillectomy according to clinical indication and written informed consent from the study patient and/or his/her guardian. The study protocol was approved by the ethics committee of Satakunta Central Hospital, Pori, Finland. Study was initiated only after obtaining written consent from the participant or his/her guardian.

Study protocol and sample collection {#Sec4}
------------------------------------

A standard questionnaire was used to obtain information on allergic diseases and respiratory symptoms within 30 days before the operation (Additional file [1](#MOESM1){ref-type="media"}: Table 1). Tonsillectomy was performed according to routine clinical procedure. Internal tonsillar tissue was immediately cut in 3--4 mm cubes, stored in RNA*late*r RNA stabilization reagent (Qiagen, Hilden, Germany), incubated at + 4 °C until next working day and finally stored at − 80 °C after removal of the non-absorbed reagent. For viral analyses, a part of the tonsils and a nasopharyngeal aspirate were stored in dry tubes at − 80 °C \[[@CR4]\]. Nasopharyngeal aspirate samples were obtained during anaesthesia using a standardized procedure \[[@CR4]\]. Serum total 25(OH)D measurement was done using an immunoassay (Abbott Architect, Chicago, USA) and bioavailable levels of 25(OH)D were estimated using additional serum measurements (D-binding protein and albumin) and published formulae.

Definitions {#Sec5}
-----------

Tonsillar hypertrophy group was defined as patients who underwent tonsillectomy because of obstructive symptoms such as snoring, breathing difficulties or swallowing problems. There were no tonsillar infection problems in this group. Recurrent tonsillitis group was defined as patients who underwent tonsillectomy because of recurrently infected tonsils (viral or bacterial) during the past 6--12 months. Those operated because of acute infection or peritonsillar abscess were excluded.

Analysis of viruses and cytokines {#Sec6}
---------------------------------

In-house real-time PCR assays were used to detect human bocavirus-1, rhinovirus, enterovirus, and respiratory syncytial virus as described previously \[[@CR4]\]. Seeplex RV12 ACE Detection (Seegene, Seoul, Korea) multiplex PCR assay was used for detection of adenovirus, coronaviruses (229E/NL63 and OC43/HKU1), influenza A and B viruses, metapneumovirus, parainfluenza virus types 1-3, respiratory syncytial virus group A and B, and rhinovirus \[[@CR4], [@CR5]\]. Virus diagnostics were carried out in the Department of Virology, University of Turku, Turku, Finland, and in the Department of Clinical Microbiology, Karolinska University Hospital, Stockholm, Sweden.

To isolate total RNA from palatine tonsils, tissues (previously stabilized in RNA*later*) were homogenized in grinding tubes containing CK28 ceramic beads by using a Precellys 24 homogenizer (Bertin Technologies, Montigny le Bretonneux, France) two times at 6000 rpm for 50 s \[[@CR4]\]. Total RNA from cell samples was isolated using the RNeasy mini kit (Qiagen, Hilden, Germany). Reverse transcription was performed with the Revert Aid M-MuLV Reverse Transcriptase (Fermentas, St. Leon-Rot, Germany) using random hexamer primers according to the manufacturers protocol. Gene expressions of IFN-α, IFN-β, IFN-γ, IL-10, IL-13, IL-17, IL-28, IL-29, IL-37, TGF-β, FOXP3, GATA3, RORC2 and Tbet were analysed by quantitative real-time PCR using iTaq SYBR Green Supermix with ROX (Bio-Rad, Hercules, CA, USA) on a 7900HT Fast Real-Time PCR instrument (Applied Biosystems, Foster City, CA, USA). Housekeeping gene elongation factor 1α (EF1α) was used for normalization. Data are shown as relative expressions, which show 2^−(ΔCT)^ values multiplied by 10^4^, where ΔCT corresponds to the difference between the CT value for the gene of interest and EF1α.

Statistical analysis {#Sec7}
--------------------

Continuous variables are described as medians and interquartile ranges, and were analysed using Mann--Whitney U test due to skewed distribution. Categorical variables are expressed as frequencies and percentages, and were analysed using Chi square test or Fisher exact test. Clinical, viral and immunological differences between study groups were analysed using unadjusted and multivariable linear regression analysis. The adjustments for immunologic analyses were chosen using backward stepwise multivariable models that initially included clinical factors and virus infections which significantly differed between the groups (age, self-reported pollen allergy, self-smoking, both adenotomy and tonsillectomy performed, respiratory symptoms one month prior to the operation and bioavailable 25(OH)D level). The final model was adjusted only for age. Before regression analyses, cytokine and transcription factor values were log-transformed because of positively skewed distributions. The mean difference was computed for log-transformed values: a recurrently infected group minus hypertrophic group. Statistical analysis was completed using JMP version 12.0.1 software (SAS Institute Inc. Cary, NC, USA). A two-sided *P* \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

Study population {#Sec9}
----------------

Originally, 200 patients participated in the study. Of them, 46 subjects did not have remaining tonsil and/or nasopharyngeal samples for the current analysis, and 11 had no intratonsillar virology done in their samples. Another 54 subjects were excluded for having mixed indications of operation other than hypertrophy or tonsillitis (Fig. [1](#Fig1){ref-type="fig"}). Thus, 89 patients comprised the analytic cohort. Forty-seven (53%) of them had tonsillar hypertrophy and 42 (47%) had recurrent tonsillitis.Fig. 1Study flow chart. ^1^8 had hypertrophy and another indication (recurrent otitis media n = 4; recurrent otitis media and fever n = 3; recurrent fever n = 1). ^2^9 had recurrent tonsillitis and another indication (recurrent fever n = 8; recurrent otitis media n = 1). ^3^21 had hypertrophy and tonsillitis; 8 had hypertrophy, tonsillitis, and another indication (recurrent fever, n = 5; recurrent otitis media, recurrent fever n = 1; recurrent otitis media n = 2). ^4^8 had other indication of operation than hypertrophy or tonsillitis (chronic white patches in tonsils n = 2; accumulation of food remnants, bad smelling breath, and feeling of beat in throat n = 1; recurrent fever n = 1; teeth braces n = 2; throat abscess n = 1; no clear cause n = 1)

Patient characteristics {#Sec10}
-----------------------

All operations were performed during afebrile period of chronic tonsil condition. Respiratory symptoms on the operation day were present equally in the hypertrophy group and the recurrent tonsillitis group (15 vs. 18%, respectively; *P* = 0.72). The median age of the patients was 8 years (range 2--46) and 20 years (range 7--60), respectively (*P* \< 0.001) (Table [1](#Tab1){ref-type="table"}). In addition to being younger, patients in the hypertrophy group had more often adenotomy and tonsillectomy done, had less self-reported pollen allergy, smoked less, and had less throat pain, but had more often rhinitis and cough 1 month prior the operation and higher bioavailable 25(OH)D level than patients in the recurrent tonsillitis group (all *P* \< 0.01) (Table [1](#Tab1){ref-type="table"}). Otherwise no significant differences were found between the two groups.Table 1Patient characteristicsCharacteristicsTonsillar hypertrophy\
n = 47Recurrent tonsillitis\
n = 42*P* valueAge, years (range)8 (2, 46)20 (7, 60)\< *0.0001*Male27 (57%)23 (55%)0.80Tonsillectomy and adenotomy28 (60%)5 (12%)\< *0.0001*Self-reported allergy20/43 (47%)23/40 (58%)0.32 Food6/43 (14%)3/39 (8%)0.38 Drug4/43 (9%)4/39 (10%)0.87 Seasonal, i.e. pollen0/43 (0%)7/39 (18%)*0.004* Perennial, i.e. animal or house dust mite3/43 (7%)2/39 (5%)0.74 Other2/43 (5%)2/39 (5%)0.90 Multiple5/43 (12%)4/39 (10%)0.86Physician-diagnosed atopic dermatitis11/44 (25%)4/38 (11%)0.09Self-reported allergic rhinitis11/44 (25%)11/39 (28%)0.74Physician-diagnosed asthma6/42 (14%)6/39 (15%)0.89Self-smoking2/43 (5%)14/40 (35%)*0.0005*Maternal smoking15/44 (34%)13/41 (32%)0.82Paternal smoking16/41 (39%)19/36 (53%)0.23Season of the surgery0.85 Winter (months 12--2)7 (15%)4 (10%) Spring (months 3--5)14 (30%)13 (31%) Summer (months 6--8)8 (17%)5 (12%) Fall (months 9--11)18 (38%)20 (48%)Respiratory symptoms The operation day6/39 (15%)7/38 (18%)0.72 Within 2 weeks16/42 (38%)12/37 (32%)0.60 Within 4 weeks23/42 (55%)18/37 (48%)0.59One month prior the operation Throat pain8/39 (21%)14/35 (40%)*0.0005* Rhinitis23/39 (59%)6/35 (17%)*0.0002* Cough15/39 (38%)5/36 (14%)*0.02* Acute otitis media2/39 (5%)0/35 (0%)0.17 Wheezing2/39 (5%)0/35 (0%)0.1725(OH)D level Total (nmol/l)56.2 (41.7, 66.9)45.7 (34.4, 72.3)0.08 Free (pg/ml)6.4 (4.9, 8.1)5.0 (3.3, 8.8)0.14 Bioavailable (ng/ml)2.2 (1.7, 2.9)1.6 (1.1, 2.7)*0.01*Values are shown as median (interquartile range, except age) or number of subjects (%). Data were analysed by Mann--Whitney U test, Chi square test, or Fisher's Exact testSignificant values are shown in italic

Viruses detected in nasopharyngeal aspirates and tonsils {#Sec11}
--------------------------------------------------------

Significantly more patients in the hypertrophy group, compared to the recurrent tonsillitis group, had a virus in their nasopharyngeal aspirates (79 vs. 38%, respectively; *P* **\<**0.001). In addition, patients in the hypertrophy group had more often adenovirus, bocavirus-1, coronavirus or rhinovirus in nasopharyngeal aspirate (all *P *\< 0.05) (Table [2](#Tab2){ref-type="table"}). However, intratonsillar virus detection didn't show statistically significant differences, except for bocavirus-1 which was detected in tonsils in 15% of patients with hypertrophy and only 2% of patients in recurrent tonsillitis group (Table [2](#Tab2){ref-type="table"}). Patients in the hypertrophy group were more often positive for one virus in their nasopharyngeal aspirates (49 vs. 24%) or two viruses in their tonsils (11 vs. 0%, respectively) (both *P *\< 0.05) (Table [2](#Tab2){ref-type="table"}).Table 2Nasopharyngeal and intratonsillar virus detectionVirusNasopharynx*P* valueTonsil*P* valueTonsillar hypertrophy\
n = 47Recurrent tonsillitis\
n = 42Tonsillar hypertrophy\
n = 47Recurrent tonsillitis\
n = 42Adenovirus9 (19%)2 (5%)*0.03*7 (15%)2 (5%)0.10Bocavirus-112 (26%)2 (5%)*0.005*7 (15%)1 (2%)*0.03*Coronavirus3 (6%)0 (0%)*0.048*0 (0%)0 (0%)--Enteroviruses4 (9%)4 (10%)0.876 (13%)4 (10%)0.63Influenza A or B virus1 (2%)0 (0%)0.260 (0%)0 (0%)--Metapneumovirus0 (0%)1 (2%)0.291 (2%)0 (0%)0.26Parainfluenza virus types 1-41 (2%)1 (2%)0.944 (9%)1 (2%)0.19Respiratory syncytial virus1 (2%)0 (0%)0.262 (4%)0 (0%)0.11Rhinovirus species A, B or C27 (57%)14 (33%)*0.02*2 (4%)2 (5%)0.91Number of positive viruses37 (79%)16 (38%)\< *0.0001*17 (36%)8 (19%)0.07Positive for 1 virus23 (49%)10 (24%)*0.01*9 (19%)7 (17%)0.76Positive for 2 viruses8 (17%)4 (10%)0.305 (11%)0 (0%)*0.01*Positive for 3 viruses5 (11%)2 (5%)0.302 (4%)1 (2%)0.62Positive for 4 viruses1 (2%)0 (0%)0.261 (2%)0 (0%)0.26Positive for ≥ 1 viruses37 (79%)16 (38%)17 (36%)8 (19%)Positive for ≥ 2 viruses14 (30%)6 (14%)8 (17%)1 (2%)Positive for ≥ 3 viruses6 (13%)2 (5%)3 (7%)1 (2%)Positive for ≥ 4 viruses1 (2%)01 (2%)0Values are shown as number of subjects (%). Data were analysed by Chi square test, or Fisher's Exact testSignificant values are shown in italic

Cytokine and transcription factor expression profiles in tonsils {#Sec12}
----------------------------------------------------------------

In unadjusted analysis, patients in the hypertrophy group had stronger tonsillar expression of Tbet (*P* = 0.03) and IL-37 (*P* = 0.001) than patients in the recurrent tonsillitis group (Tables [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}). In the multivariable regression analysis, only age remained as a significant co-factor (Table [4](#Tab4){ref-type="table"}). After adjustment for age, the expressions of only IL-37 was independently associated with tonsillar hypertrophy group (*P* \< 0.05, Fig. [2](#Fig2){ref-type="fig"}). No other differences in cytokine or transcription factor expression were found between the groups.Table 3Intratonsillar cytokine and transcription factor expression in hypertrophic tonsils and recurrent tonsillitisCytokine or transcription factorTonsillar hypertrophy\
n = 47Recurrent tonsillitis\
n = 42Median (IQR)Median (IQR)T-helper~1~ IFN-γ58 (37, 90)76 (32, 117) Tbet54 (31, 83)34 (22, 60)T-helper~2~ IL-131.2 (0.03, 3.7)0.45 (0.02, 2.2) GATA327 (16, 36)18 (12, 39)T-helper~17~ IL-1710 (5.6, 19)7.3 (4.1, 13) RORC215 (7.2, 31)20 (10, 28)T-regulatory IL-1049 (24, 74)35 (21, 64) IL-370.26 (0.15, 0.37)0.14 (0.10, 0.24) FOXP346 (20, 87)48 (24, 80) TGF-β163 (105, 232)171 (120, 225)Type I/III interferons IFN-α15 (0.59, 62)9.7 (0.27, 56) IFN-β24 (2.7, 101)22 (2.1, 103) IL-2831 (3.1, 88)12 (1.4, 75) IL-2911 (2.3, 34)3.7 (1.3, 26)Values are arbitrary units × 10^4^ relative to EF1αIQR, interquartile range; IFN, interferon; Tbet, T-box transcription factor; IL, interleukin; GATA3, GATA-binding factor 3; RORC, RAR-related orphan receptor C; FOXP, forkhead box protein; TGF, tumour growth factor Table 4Differences in cytokine and transcription factor expression between hypertrophic tonsils and recurrent tonsillitisCytokine or transcription factorMean differences recurrently infected minus hypertrophic groupUnivariateMultivariatenDifference of means (95% CI)Adjusted difference of means (95% CI)AdjustmentsT-helper~1~ IFN-γ880.061 (− 0.32, 0.44)\
P = 0.75---- Tbet89− *0.40 (*− *0.76,* − *0.034)*\
*P *= *0.03*− 0.21 (− 0.61, 0.18)\
P = 0.29AgeT-helper~2~ IL-1389− 0.74 (− 1.8, 0.36)\
P = 0.18---- GATA389− 0.12 (− 0.42, 0.18)\
P = 0.43----T-helper~17~ IL-1789− 0.35 (− 0.80, 0.096)\
P = 0.12− 0.087 (− 0.57, 0.40)\
P = 0.72Age RORC2890.014 (− 0.35, 0.38)\
P = 0.94----T-regulatory IL-1089− 0.26 (− 0.61, 0.0871)\
P = 0.14− 0.0070 (− 0.38, 0.36)\
P = 0.97Age IL-3787− *0.48 (*− *0.77,* − *0.19)*\
*P *= *0.001*− *0.31 (*− *0.63,* − *0.0021)*\
*P *= *0.049*Age FOXP3890.091 (− 0.31, 0.49)\
P = 0.65---- TGF-β89− 0.0077 (− 0.32, 0.30)\
P = 0.96----Type I/III interferons IFN-α87− 0.41 (− 1.5, 0.7)\
P = 0.47---- IFN-β88− 0.21 (− 1.0, 0.61)\
P = 0.62---- IL-2889− 0.64 (− 1.5, 0.2)\
P = 0.13---- IL-2987− 0.57 (− 1.5, 0.31)\
P = 0.15----Data are expressed as mean differences as a recurrently infected group minus hypertrophic group. The data were analysed using backward stepwise linear regression analysis after logarithmic transformation. Only significant co-factors were used as adjustments in the final modelCI, confidence interval; IFN, interferon; Tbet, T-box transcription factor; IL, interleukin; GATA3, GATA-binding factor 3; RORC, RAR-related orphan receptor C; FOXP, forkhead box protein; TGF, tumour growth factorSignificant values are shown in italic Fig. 2Relative tonsillar expression of IL-37. Forty-two recurrent tonsillitis samples compared with 47 hypertrophic tonsil samples. Values are arbitrary units x 10^4^ relative to EF1α. Data are represented as median with interquartile range. IL-37, Interleukin 37

Discussion {#Sec13}
==========

This study shows differences in virus detections and T cell and interferon gene expressions in patients undergoing tonsillectomy due to tonsillar hypertrophy or recurrent tonsillitis. Patients with tonsillar hypertrophy were typically younger, and had more viral findings, but only bocavirus-1 was more often found in tonsils when compared to patients with recurrent tonsillitis. Respectively, they also had less self-reported pollen allergy, but no differences were found in food allergies between the groups. After age-adjusted analysis, tonsillar hypertrophy was associated with higher tonsillar mRNA expressions of IL-37. Other than age, no other significant co-factors were found.

IL-37 (formerly IL-1 family member 7) is a fundamental inhibitor of innate immunity \[[@CR9], [@CR10]\]. It has been shown to be expressed in macrophages, monocytes, plasma and epithelial cells \[[@CR11]\]. After ligand activation, IL-37 inhibits inflammatory cytokines (especially IL-1β, but also IL-6, IL-7, IFN-γ, and TNF-α) and augments the level of anti-inflammatory IL-10 and T regulatory cells \[[@CR11]\]. We have previously shown that the expression of IL-37 is closely and positively associated with other "immune activation/regulatory" cytokines (IL-10, IL-17, IL-37, TGF-β, FOXP3, GATA3, RORC2, Tbet) in tonsils \[[@CR2]\]. The current analysis adds that tonsillar expression of anti-inflammatory cytokine IL-37 is also independently and positively associated with tonsillar hypertrophy.

Interferons (IFN-α, IFN-β, IFN-γ, IL-28, IL-29) are cytokines with antiviral activity and their expression is induced by viral infection. IL-28 and IL-29 are members of IFN-λ family \[[@CR12], [@CR13]\]. They are produced by dendritic cells and macrophages following viral infection or activation with bacterial components \[[@CR12]--[@CR14]\]. We expected to see differences in IFN expression (lower responses in recurrent tonsillitis than in tonsillar hypertophy group), since they have antiviral properties and they up-regulate the expression of MHC Class II molecules on cells which increases the immune system's ability to recognize viruses \[[@CR14], [@CR15]\]. However, we did not observe these differences. We speculate that tonsillar hypertophy may be a consequence of chronic inflammation in tonsils and the same interferon pathways are equally activated in both conditions. We have previously found strong intragroup correlations of tonsillar IFN expression(IFN-α, IFN-β, IFN-γ, IL-28) \[[@CR2]\].

Age was the main clinical characteristic differentiating the tonsillectomy indication groups. In agreement with previous findings \[[@CR16]\], we found that obstruction due to the hypertrophy is more common with younger children where as adults have more recurrent tonsillitis. The age difference between the groups also explains the differences in smoking and in additional adenotomy performed. Interestingly, Reis and colleagues found no difference between the age distribution of hypertrophy and tonsillitis patients, but the narrow age range of their subjects (ages 2--11 years) may explain the lack of difference \[[@CR17]\].

Virus was found in the nasopharynx of 79% of patients with tonsillar hypertrophy group and 38% in recurrent tonsillitis group. Most often detected viruses were adenovirus, bocavirus-1, coronavirus and rhinovirus. However, intratonsillar virus detection was low and did not show any statistically significant differences except for bocavirus-1. The results of nasopharyngeal and intratonsillar virus detection vs tonsillar cytokine responses are discussed in detail in our previous report \[[@CR2]\].

Small differences in cytokine expression may partly be explained by differences concerning tonsillar germinal centers. The mean follicular area has been found to be larger, and the number of germinal centers higher, in the hypertrophy group compared to the recurrent tonsillitis \[[@CR17]--[@CR19]\]. In our study, the samples were taken from inside of the tonsils to minimize the margin of error and the possibility to misinterpreted differences between the groups. Seasonal changes, e.g. pollen and influenza seasons, may affect the expression of peripheral T cells \[[@CR20]\], but we found no differences in tonsillar expression of cytokines between the seasons of the surgery. Also, respiratory viruses are continuously detected in children with chronic tonsillitis throughout the year \[[@CR21]--[@CR23]\]. Circulating serum 25(OH)D level has been shown to been positively associated with IL-37 level \[[@CR3]\], but here it did not confound the results.

A limitation of the current study is that we did not investigate bacterial colonization of the tonsils in these patients due to fact that the operation was done during an afebrile period of their chronic tonsil condition. The downstream signaling of IL-37 is a complex process and to show functionality of IL-37 by downstream mediators was not in the scope of this study. In addition to forming cell-surface receptor complexes, IL-37 translocates to the nucleus where it binds to nuclear DNA and participate in transcription. \[[@CR24], [@CR25]\] IL-37 is regarded as a "dual function" cytokine, similar to IL-1α and IL-33.

Conclusions {#Sec14}
===========

In summary, this study provides new insights about T cell research in lymphoid tissue from the clinical aspect of the surgical indication for tonsillectomy. We found tonsils as a good in vivo model for investigating the mechanisms of inflammatory processes and infections in lymphoid organs. Our data suggest that T-cell and interferon gene expressions appear to relatively stable over the two main indications of tonsillectomy, tonsillar hypertrophy and recurrent tonsillitis. However, anti-inflammatory immune responses, namely IL-37, might be slightly stronger in patients with tonsillar hypertrophy than with patients with recurrent tonsillitis.
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